Corgentech Inc. Competitors

We envision a world where our technology is amplified to touch the lives of billions, sparking transformation in global health.

Adaptimmune is a fully integrated cell therapy company, designed and built from the ground up with four U.K.- and U.S.-based biotechnology hub locations. Our comprehensive capabilities and teams include preclinical research, clinical development, translational sciences, autologous and allogeneic manufacturing, and in-house commercial and corporate operations. For more information about Adaptimmune, please visit www.adaptimmune.com. If interested in joining our fast growing team, click on the careers tab of this page. Adaptimmune only accepts employment applications through our corporate website at Adaptimmune.com/Careers and through the ‘Easy Apply’ feature on LinkedIn. If you receive an unsolicited message from someone purporting to represent Adaptimmune, please be cautious and do not provide any personal or financial information, except through the approved application process. If you have any questions regarding an unsolicited message or offer, please contact Talent.AcquisitionUSA@adaptimmune.com to confirm whether the communication is legitimate.

CureVac (Nasdaq: CVAC) is a pioneering multinational biotech company founded in 2000 to advance the field of messenger RNA (mRNA) technology for application in human medicine. In more than two decades of developing, optimizing, and manufacturing this versatile biological molecule for medical purposes, CureVac has introduced and refined key underlying technologies that were essential to the production of mRNA vaccines against COVID-19, and is currently laying the groundwork for application of mRNA in new therapeutic areas of major unmet need. CureVac is leveraging mRNA technology, combined with advanced omics and computational tools, to design and develop off-the-shelf and personalized cancer vaccine product candidates. It also develops programs in prophylactic vaccines and in treatments that enable the human body to produce its own therapeutic proteins. Headquartered in Tübingen, Germany, CureVac also operates sites in the Netherlands, Belgium, Switzerland, and the U.S. Further information can be found at www.curevac.com.